HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Massimo Cristofanilli Selected Research

Fulvestrant (Faslodex)

1/2022Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
1/2021Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3.
1/2021Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
10/2019Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
2/2019Palbociclib and Fulvestrant in Breast Cancer. Reply.
11/2018Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
11/2018Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
11/2018The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.
1/2018Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.
1/2017Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Massimo Cristofanilli Research Topics

Disease

169Breast Neoplasms (Breast Cancer)
06/2022 - 04/2002
146Neoplasms (Cancer)
06/2022 - 10/2002
41Inflammatory Breast Neoplasms
06/2022 - 01/2003
38Neoplasm Metastasis (Metastasis)
01/2022 - 10/2002
36Circulating Neoplastic Cells
02/2022 - 03/2005
15Triple Negative Breast Neoplasms
01/2022 - 03/2008
12Disease Progression
01/2022 - 04/2002
11Pathologic Complete Response
10/2013 - 06/2005
9Neutropenia
01/2021 - 05/2012
5Prostatic Neoplasms (Prostate Cancer)
01/2018 - 01/2003
4Infections
01/2021 - 05/2012
4Febrile Neutropenia
01/2021 - 07/2015
4Lung Neoplasms (Lung Cancer)
06/2019 - 08/2008
4Anemia
09/2018 - 11/2014
4Carcinoma (Carcinomatosis)
10/2016 - 04/2003
3Carcinogenesis
12/2020 - 12/2014
3Fatigue
01/2020 - 07/2015
3Exanthema (Rash)
01/2020 - 11/2016
3Pleural Effusion (Pleural Effusions)
10/2016 - 06/2010
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/2021 - 11/2017
2Diarrhea
01/2020 - 11/2016
2Noninfiltrating Intraductal Carcinoma (DCIS)
08/2019 - 10/2016
2Thrombocytopenia (Thrombopenia)
09/2018 - 07/2015
2Hypothyroidism
01/2017 - 06/2009
2Leukopenia
01/2017 - 07/2015

Drug/Important Bio-Agent (IBA)

45Hormones (Hormone)IBA
01/2022 - 01/2004
30Biomarkers (Surrogate Marker)IBA
01/2022 - 12/2006
26Estrogen ReceptorsIBA
06/2022 - 02/2004
25palbociclibIBA
06/2022 - 07/2015
19ErbB Receptors (EGF Receptor)IBA
01/2022 - 06/2005
19Biological ProductsIBA
12/2021 - 10/2002
17Circulating Tumor DNAIBA
06/2022 - 01/2013
17Proteins (Proteins, Gene)FDA Link
01/2022 - 02/2003
14Fulvestrant (Faslodex)FDA Link
01/2022 - 07/2015
13Paclitaxel (Taxol)FDA LinkGeneric
11/2019 - 02/2004
12AnthracyclinesIBA
01/2012 - 04/2002
11Doxorubicin (Adriamycin)FDA LinkGeneric
12/2018 - 01/2003
10Pharmaceutical PreparationsIBA
01/2022 - 12/2008
10Cell-Free Nucleic AcidsIBA
11/2021 - 10/2016
9Docetaxel (Taxotere)FDA Link
12/2018 - 04/2002
9human ERBB2 proteinIBA
11/2018 - 06/2005
8DNA (Deoxyribonucleic Acid)IBA
08/2021 - 05/2016
8Trastuzumab (Herceptin)FDA Link
09/2018 - 04/2002
8Progesterone Receptors (Progesterone Receptor)IBA
08/2015 - 12/2006
7Cyclophosphamide (Cytoxan)FDA LinkGeneric
10/2013 - 07/2003
6Messenger RNA (mRNA)IBA
06/2019 - 09/2005
6Estrogens (Estrogen)FDA Link
04/2013 - 07/2003
6Taxoids (Taxanes)IBA
01/2012 - 05/2002
6Fluorouracil (Carac)FDA LinkGeneric
03/2010 - 05/2002
5Immune Checkpoint InhibitorsIBA
05/2022 - 01/2017
5Chemokine ReceptorsIBA
01/2022 - 06/2007
5Cyclin-Dependent Kinase 4IBA
01/2021 - 01/2017
5AntibodiesIBA
01/2021 - 01/2003
5Cyclin-Dependent Kinases (cdk Proteins)IBA
11/2020 - 10/2006
4Epithelial Cell Adhesion MoleculeIBA
01/2022 - 06/2009
4Monoclonal AntibodiesIBA
01/2021 - 02/2003
4Phenobarbital (Luminal)FDA Link
11/2020 - 08/2005
4Peptides (Polypeptides)IBA
01/2020 - 01/2003
4taxaneIBA
09/2018 - 09/2003
4Epidermal Growth Factor (EGF)IBA
11/2017 - 06/2010
4Cadherins (E-Cadherin)IBA
04/2016 - 12/2006
4Lapatinib (GW572016)FDA Link
01/2013 - 06/2010
4Transcription Factors (Transcription Factor)IBA
11/2012 - 12/2005
3ChemokinesIBA
01/2022 - 06/2007
3RNA (Ribonucleic Acid)IBA
01/2022 - 06/2019
3LigandsIBA
01/2021 - 07/2004
3TamoxifenFDA LinkGeneric
01/2020 - 05/2005
3MicroRNAs (MicroRNA)IBA
01/2018 - 07/2010
3AntigensIBA
01/2018 - 02/2007
3Anastrozole (Arimidex)FDA LinkGeneric
11/2016 - 03/2010
3Tumor Biomarkers (Tumor Markers)IBA
05/2016 - 10/2002
3Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
08/2010 - 02/2009
3Cyclooxygenase 2 (Cyclooxygenase-2)IBA
06/2010 - 01/2008
3ParaffinIBA
05/2005 - 11/2003
2Phosphotransferases (Kinase)IBA
01/2022 - 01/2021
2Letrozole (Femara)FDA LinkGeneric
01/2021 - 01/2020
2CytokinesIBA
01/2021 - 08/2019
2Poly(ADP-ribose) Polymerase InhibitorsIBA
12/2020 - 01/2020
2Capecitabine (Xeloda)FDA Link
01/2020 - 06/2010
2CyclinsIBA
10/2019 - 01/2019
2exemestane (Aromasin)FDA Link
01/2019 - 01/2016
2Antineoplastic Agents (Antineoplastics)IBA
12/2018 - 10/2013
2EnzymesIBA
09/2018 - 09/2009
2Anaplastic Lymphoma KinaseIBA
01/2018 - 01/2013
2Thymidine KinaseIBA
01/2018 - 11/2016
2Genetic Markers (Genetic Marker)IBA
06/2017 - 10/2014
2Cell Surface ReceptorsIBA
11/2016 - 05/2005
2AZD 8931IBA
11/2016 - 05/2014
2Aromatase InhibitorsIBA
01/2016 - 01/2004
2HematinicsIBA
09/2015 - 11/2014
2fibrin fragment D (D-dimer)IBA
03/2015 - 03/2015

Therapy/Procedure

111Therapeutics
01/2022 - 04/2002
42Drug Therapy (Chemotherapy)
01/2022 - 04/2002
17Neoadjuvant Therapy
05/2019 - 04/2003
11Radiotherapy
01/2018 - 02/2004
7Precision Medicine
11/2021 - 11/2016
4Immunotherapy
05/2022 - 01/2018
4Drug Tapering
12/2020 - 05/2012
4Segmental Mastectomy (Lumpectomy)
01/2018 - 09/2004
3Mastectomy (Mammectomy)
10/2016 - 09/2004